Source - RNS
RNS Number : 6022A
Bank of America Merrill Lynch
22 January 2020
 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

BofA Securities, Inc.

Company dealt in

Allergan PLC

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - IE00BY9D5467

Date of dealing

21/01/2020

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

IE00BY9D5467


Long

Short

Number

%

Number

%

(1)

Relevant securities

1,934,243

0.589%

1,429,389

0.435 %

(2)

Derivatives (other than options):

1,864,967

0.568%

2,023,221

0.616%

(3)

Options and agreements to purchase/sell:

75,000

0.023%

0

0%

Total

3,874,210

1.18%

3,452,610

1.051%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

                                 28,126

 192.58 USD

 Purchase

                                     100

 192.08 USD

 Purchase

                                     200

 192.09 USD

 Purchase

                                     115

 192.15 USD

 Purchase

                                     100

 192.38 USD

 Purchase

                                         5

 192.39 USD

 Purchase

                                     116

 192.4 USD

 Purchase

                                     231

 192.42 USD

 Purchase

                                     116

 192.43 USD

 Purchase

                                     305

 192.44 USD

 Purchase

                                  1,084

 192.45 USD

 Purchase

                                  1,927

 192.46 USD

 Purchase

                                  1,196

 192.47 USD

 Purchase

                                  1,977

 192.48 USD

 Purchase

                                  1,646

 192.49 USD

 Purchase

                                     500

 192.5 USD

 Purchase

                                     330

 192.52 USD

 Purchase

                                     100

 192.54 USD

 Purchase

                                     146

 192.55 USD

 Purchase

                                       49

 192.56 USD

 Purchase

                                     635

 192.57 USD

 Purchase

                                  1,900

 192.58 USD

 Purchase

                                     115

 192.87 USD

 

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

                                 28,588

 192.58 USD

 Sale

                                     112

 192.7 USD

 Sale

                                     120

 192.71 USD

 Sale

                                     116

 192.78 USD

 Sale

                                       96

 192.8 USD

 Sale

                                       16

 192.81 USD

 Sale

                                     612

 192.82 USD

 Sale

                                  2,186

 192.83 USD

 Sale

                                     100

 192.831 USD

 Sale

                                     840

 192.84 USD

 Sale

                                     577

 192.85 USD

 Sale

                                     100

 192.86 USD

 Sale

                                     153

 192.88 USD

 Sale

                                  1,124

 192.89 USD

 Sale

                                  1,694

 192.9 USD

 Sale

                                  2,206

 192.91 USD

 Sale

                                     878

 192.92 USD

 Sale

                                  4,422

 192.93 USD

 Sale

                                       14

 192.931 USD

 Sale

                                  2,209

 192.94 USD

 Sale

                                     873

 192.95 USD

 Sale

                                     582

 192.96 USD

 Sale

                                     274

 192.97 USD

 Sale

                                     348

 192.98 USD

 Sale

                                       49

 192.99 USD

 Sale

                                     100

 193 USD

 Sale

                                     115

 193.03 USD

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

Swaps

Reducing a Short Position

50

192.68 USD

Swaps

Reducing a Short Position

59

192.68 USD

Swaps

Reducing a Short Position

124

192.68 USD

Swaps

Reducing a Short Position

388

192.68 USD

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)




Loan

Loan of 64,800 shares

N/A

Collateral Delivery

Collateral Delivery of 3,900 shares

N/A

Collateral Delivery

Collateral Delivery of 91,000 shares

N/A

Collateral Delivery

Collateral Delivery of 16,200 shares

N/A

Collateral Delivery

Collateral Delivery of 125,000 shares

N/A

Collateral Delivery

Collateral Delivery of 22,500 shares

N/A

Collateral Delivery

Collateral Delivery of 28,000 shares

N/A

Collateral Delivery

Collateral Delivery of 28,500 shares

N/A

Collateral Delivery

Collateral Delivery of 48,800 shares

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

Yes

 

Date of disclosure

22/01/2020

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offeror with which connected

AbbVie Inc

Nature of connection (Note 9)

Advisor to - AbbVie Inc

 

 

SUPPLEMENTAL FORM 38.5(b)


DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

Product name,
e.g. call option

Written or
purchased

Number of securities to which the option or derivative relates

Exercise price
(Note 2)

Type, e.g.
American,
European etc

Expiry date

Put Option

Purchased

         75,000

160 USD

 American

21/02/2020

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFFLLIIFFII
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.